Literature DB >> 30213198

Cervical Cancer, Human Papillomavirus Infection, and Vaccine-Related Knowledge: Awareness in Chinese Women.

Li Yuanyue1,2, Zulqarnain Baloch3, Li Shanshan4,2, Nafeesa Yasmeen5, Wu Xiaomei6, Jamal Muhammad Khan7, Xia Xueshan1.   

Abstract

Cervical cancer (CC) has a high incidence and mortality and is accompanied by lack of organized CC screening programs, lack of health-care facilities, and a lack of human papillomavirus (HPV) vaccination among female population in the world, particularly China. We recruited 487 females who visited the outpatient department of the First People's Hospital of Yunnan Province from November 2015 to January 2016 to complete a standardized-designed questionnaire. We found that only 39.6% of the females knew about the role of HPVs in the development of cervical cancer. Moreover, none of the females knew that HPV could cause penile carcinomas, perianal carcinomas, and head and neck carcinomas. The majority of the participants acquired information about cervical cancer, HPV, and the HPV vaccine from medical workers. Only 15.6% of the recruited females had heard about the HPV vaccine. The overall HPV vaccine acceptance rate was higher (91.2%) if the vaccine was available free of cost. In this study, we found high acceptability of the HPV vaccine in Chinese women and high awareness about cervical cancer. However, very low levels of knowledge about HPVs and their role in cancer development among the recruited women is alarming. Therefore, it is very important to initiate educational programs to raise awareness and knowledge about cervical cancer, HPV, and the HPV vaccine in this region.

Entities:  

Keywords:  HPV; Yunnan; cervical cancer; vaccine

Mesh:

Substances:

Year:  2018        PMID: 30213198      PMCID: PMC6144517          DOI: 10.1177/1073274818799306

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


Background

The human papillomavirus (HPV) is one of the most common sexually transmitted infections of the reproductive tract in the world.[1] The roles of high-risk HPVs (HR-HPVs) in different cancers, including oropharyngeal, anal, cervical, vaginal, vulvar, and penile, have been established.[2] The incidence of HPV-associated cancers has increased over the last 50 years, and the predominance has shifted from a female to a male cancer.[2-4] Cervical cancer is one of the most preventable human cancers; its prevention is based on early diagnosis and treatment.[4,5] The prevalence and mortality of cervical cancer have significantly decreased in developed nations due to widespread applications of Pap smear tests and vaccination. However, developing countries lack well-organized screening programs, which results in greater mortalities in these countries.[6] According to the World Health Organization and the estimates of different published studies, there are 3 leading causes of the increased cervical cancer prevalence and mortality in developing countries of the world: (1) a lack of well-organized cervical cancer screening programs, (2) a lack of health-care facilities, and (3) a lack of HPV vaccination among female population in the world particularly China.[7-9] Knowledge and awareness about cervical cancer, HPV, and the efficacy of the HPV vaccine in the prevention of cervical cancer are very low in the world, especially in China. Some studies have demonstrated that awareness about cervical cancer and HPV is substantially different among different populations in China.[10-12] Moreover, previously reported studies from various well-developed areas in China with high levels of social and economic disparity make the findings less applicable to all of China.[12] Therefore, the current study was designed to assess the following: (1) knowledge in HPV positive versus HPV negative women about cervical cancer, HPV and the HPV vaccine among Chinese women in the Yunnan province, (2) the factors associated with knowledge about HPV, the HPV vaccine, and HPV-associated cancers.

Methodology

Type of Study

This is a cross-sectional descriptive study. The questionnaires were administered by an interviewer; every women who had an appointment was invited to participate. A standardized questionnaire was designed based on previously published study.[13]

Ethical Approval

All the participants voluntarily signed the documented consent prior to their participation, and the security, anonymity, and the privacy of participants were respected rigorously in this study. The ethics committee of the Kunming University of Science and Technology formally reviewed and approved our study.

Study Population

This survey was conducted by the Faculty of Life Science and Technology of Kunming University of Science and Technology in partnership with the First Peoples’ Hospital of Yunnan Province. Women who visited the outpatient department of the First Peoples’ Hospital of Yunnan Province were recruited from November 2015 to January 2016. A copy of the questionnaire was sent to a gynecologist who worked in the outpatient department of the Yunnan First Peoples’ Hospital. She agreed to appoint female doctors for the collection of data from the patients. Before beginning the interview, a cover letter that described the aim of the study, conveyed a guarantee of secrecy, and highlighted that the patient’s decision to participate would not affect her medical checkup was given to the patient. The overall response rate was 74.9% (487/675). All women were interviewed by a trained interviewer in their local Chinese dialect in an isolated room using a standardized questionnaire to elicit information about the subjects’ demographic and social variables, sexual behavior, medical and reproductive histories, and smoking and drinking habits. After questioner process, a qualified gynecologist did the pelvic examination and sample collection process. One cervical sample was collected with a cyto-brush (Hybribio) for HPV diagnosis.

DNA Extractions and HPV Testing

The DNA extraction process was completed through the DNA Extraction Kit (Qiagen, Valencia, California) by following the recommendation of manufacturer. Samples that tested positive for β-globin were analyzed by polymerase chain reaction (PCR) amplification of HPV DNA. The HPV-positive samples were confirmed by PCR with universal L1 primer MY09/11 and GP5/6 systems; DNA from HeLa and Caski cell lines was used as positive controls, and mixtures without sample DNA were used as negative controls. The HPV genotypes were determined using an HPV GenoArray Test Kit (Hybribio, Chaozhou, China), according to the manufacturer’s instructions. Geno-Array is an L1 consensus primer-based PCR assay that is capable of amplifying 23 HPV genotypes, including 13 HR-HPV genotypes (HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), 3 Potential High-Risk (PHR)-HPV genotypes (HPV-53, 66, and 81), and 7 low-risk HPV genotypes (HPV-6, 11, 42, 43, 44, and 61).

Data Analysis

The data collected from the participants were transferred into a database, and descriptive and inferential statistics were applied using SPSS version 20.0 (SPSS Inc, Chicago, Illinois, for Windows). The participants were divided into HPV-positive and HPV-negative subgroups to examine the relationships of cervical cancer with the HPV-related knowledge, attitudes, behaviors, and intentions of the participants. We applied the χ2 test to examine differences between the groups. Awareness and knowledge about HPV, cervical cancer, and the HPV-vaccine are presented as percentages. The associations of various variables with the knowledge and awareness about cervical cancer, HPV, and the HPV vaccine were calculated with a logistic regression model. All statistical tests were 2-sided, and P values <.05 were considered statistically significant.

Results

A total of 487 women were included in this study. Among them, 92 were found to be HPV DNA-positive (18.9%, 92/487), and 395 were HPV-negative. The mean age of the 487 women was 38.3 years (38.3 ± 9.0, confidence interval [CI]: 37.4-39.1), and there was no significant difference in age between the HPV-negative (38.3 years [median = 38], standard deviation [SD] = 9.1, CI: 37.4-39.2) and HPV-positive groups (38.1 years [median = 38], SD = 9.4, CI: 36.1-40.0; P = .81). The sociodemographic characteristics are presented in Table 1.
Table 1.

Demographic Characteristics of the Participants.

CharacteristicFrequencyPercent
Ethnicity
 Han40683.4
 Other8116.6
Region
 East28157.7
 other region9820.1
 Other province10822.2
Age
 ≤296312.9
 30-3915431.6
 40-4918037.0
 ≥509018.5
Religious beliefs
 Yes224.5
 No46595.5
Education
 Illiterate and primary school8419.3
 Secondary school25552.4
 College and above13828.3
Occupation
 Farmer7114.6
 Staff12826.2
 Self-employed and service15431.6
 Other13427.5
Marital status
 Married45894.0
 Single296.0
Monthly Income
 <300020842.7
 3000-500011623.8
 5100-80008517.5
 >50007816.0
Smoking
 Yes102.1
 No47797.9
Drinking
 Yes367.4
 No45192.6
Contraceptive methods
 Condom19339.6
 Intrauterine Device (IUD)12024.6
 Others5711.7
 None11724.1
Number of sexual partners
 138178.2
 27715.8
 ≥3296.0
The age of first sex
 ≤2015732.2
 21-2317636.1
 ≥2415431.7
Sexual frequency
 ≥1/week27857.1
 >1/week20942.9
Childbearing history
 07515.4
 123949.1
 ≥217335.5
Demographic Characteristics of the Participants. A total of 78.6% (383/487) women had heard about cervical cancer. Knowledge about cervical cancer prevention through screening was significantly higher among the HPV-negative group (55.9%) than the HPV-positive group (67.4%). Fifty-eight percentage (251/487) of the participants had acquired information about cervical cancer from medical workers. Medical workers acted as a source of knowledge about cervical cancer for significantly more of the HPV-positive women (66.7%) than the HPV-negative women (58.9%). Similarly, the levels of knowledge about HPV and its role in cervical cancer were higher among the HPV-negative women (HPV: 53.2, role in cervical cancer [CC] 38.7%) than the HPV-positive women (HPV: 42.4, role in CC 43.5%). The level of knowledge about the role of HPV in other related cancers was significantly higher among the HPV-positive women (20.6%) than the HPV-negative women (9.1%; Table 2).
Table 2.

Levels of Knowledge About HPV and Its Vaccination Among the HPV-Positive and HPV-Negative Groups.a

VariableTotalHPV Positive (n = 92)HPV Negative (n = 395) P Value
Do you know about cervical cancer?416 (85.4)75 (81.5)341 (86.3).239
Do you know that cancer can be prevented with cervical cancer screening tests?383 (78.6)68 (73.9)315 (79.7).26
Have you undergone a cervical cancer screening?283 (58.1)62 (67.4)221 (55.9).045
Is your main source of information about cervical cancer a medical worker?251 (51.5)50 (66.7)201 (58.9).005
Do you know about HPV?249 (51.1)39 (42.4)210 (53.2).063
Do you know that HPV can transmit through sex?150 (30.8)30 (32.6)120 (30.4).257
Do you know that HPV infection can lead to cervical cancer?193 (39.6)40 (43.5)153 (38.7).402
Do you know that HPV can cause other related cancers?55 (11.3)19 (20.6)36 (9.1).002
Is your main source of information about HPV a medical worker?183 (37.6)25 (64.1)158 (75.2).300
Do you know about the HPV vaccine?75 (15.4)23 (25.0)53 (13.8).006
Do you know that the HPV vaccine can prevent cervical cancer and other related cancers?55 (11.3)19 (20.6)36 (9.1).002
Is the HPV vaccine only for women?48792 (100)395 (100)-
Are you willing to be vaccinated if the vaccine is free of charge?444 (91.2)86 (93.5)358 (90.6).687

Abbrevaition: HPV, human papillomavirus.

aThe variables indicate significant differences (P = .05); n = number of participants.

Levels of Knowledge About HPV and Its Vaccination Among the HPV-Positive and HPV-Negative Groups.a Abbrevaition: HPV, human papillomavirus. aThe variables indicate significant differences (P = .05); n = number of participants. The overall levels of awareness and knowledge about the HPV vaccine were very low among both groups. The levels of knowledge about the HPV vaccine and its role in cervical cancer prevention were significantly higher among the HPV-positive (25.0%, role in CC prevention: 20.6%) women than the HPV-negative women (13.8%, role in CC prevention: 9.1%). The level of willingness to receive the HPV vaccine was high in both groups. Surprisingly, none of the women knew that HPV vaccine could also be used for men (0%, 0/487). We also collected data regarding the participants’ high or low levels of knowledge and awareness about the risk factors for cervical cancer (Table 3), HPV (Table 4) and the HPV vaccine (Table 5). The levels of knowledge and awareness about cervical cancer and HPV were significantly higher among populations with higher education levels, higher income, and higher job status (Tables 3 and4). Furthermore, migrant women (P = .004), women of other ethnicities (P = .028), older women, and married women had significantly higher levels of knowledge about cervical cancer and HPV (Tables 3 and 4). The levels of knowledge and awareness about the HPV vaccine were low among all groups and were significantly lower among the illiterate (P = .001) and agricultural workers (P = .004; Table 5).
Table 3.

Logistic Regression Analysis of the Levels of Knowledge About Cervical Cancer.

CharacteristicTotalKnowledgeOR (95%CI) P Value
Residence.040
 East281250 (89.0%)1
 Another region9875 (76.5%)2.56 (1.17-5.60)
 Other province10892 (85.2%)1.06 (0.48-2.32)
Ethnicity.028
 Han406352 (86.7%)1
 Other8165 (80.2%)2.59 (1.11-6.05)
Age.074
 ≤296346 (73.0%)1
 30-39154128 (83.1%)0.49 (0.17-1.34)
 40-49180162 (90%)0.94 (0.32-2.76)
 ≥509081 (90%)1.72 (0.51-5.81)
Occupation.374
 Farmer7148 (67.6%)1
 Staff128116 (90.6%)1.06 (0.37-3.06)
 Self-employed154138 (89.6%)0.64 (0.24 -1.66)
 Other134115 (86.8%)0.53 (0.22 -1.25)
Education.480
 Illiterate and primary8463 (75%)1
 Secondary school255216 (84.7%)0.64 (0.24-1.66)
 College and above138117 (84.8%)0.00 (0.00-)
Monthly income.620
 <3000208180 (86.5%)1
 3000-500011698 (84.5%)1.36 (0.61-3.06)
 5100-80008570 (82.4%)1.63 (0.69-3.85)
 >80007869 (88.5%)0.53 (0.22 -1.25)
Religious belief.606
 Yes2220 (90.9%)1
 No465397 (85.4%)0.64 (0.12-3.42)
Marital status.924
 Married458390 (85.2%)1
 Single2922 (75.9%)0.93 (0.19-4.44)
Childbearing history.262
 07573 (97.3%)1
 1239216 (90.4%)0.94 (0.40-2.20)
 >2173127 (73.4%)1.10 (0.36-3.42)
Age at first sexual experience.007
 ≤20157125 (79.6%)1
 21-23176142 (80.7%)1.05 (0.53-2.08)
 ≥24154149 (96.8%)0.18 (0.06-0.57)
Number of sexual partners.325
 1381323 (84.8%)1
 27766 (85.7%)2.03 (0.72-5.75)
 ≥32927 (93.1%)0.73 (0.11-5.00)
Sexual frequency.034
 ≥1/week278245 (88.1%)1
 <1/week209171 (81.8%)1.98 (1.05-3.73)
Contraceptive method.131
 Condom193184 (95.3%)1
 IUD120100 (83.3%)2.53 (0.96-6.70)
 Other5742 (73.7%)2.10 (0.72-5.75)
 None11790 (77.0%)3.10 (1.17-8.11)
Smoking.893
 Yes108 (80.0%)1
 No477408 (85.5%)0.85 (0.08-8.94)
Drinking.662
 Yes3631 (86.1%)1
 No451385 (85.4%)0.74 (0.19-2.89)

Abbreviations: CI confidence interval; IUD, intrauterine device; OR, odds ratio.

Table 4.

Logistic Regression Analysis of the Levels of Knowledge about HPV.

CharacteristicTotalKnowledgeOR (95%CI) P Value
Residence.696
 East281151 (53.7%)1
 Other region9850 (51.0%)0.79 (0.45-1.38)
 Other province10848 (44.4%)0.90 (0.53 -1.55)
Ethnicity.151
 Han406209 (51.5%)1
 Other8140 (49.4%)1.55 (0.85-2.82)
Age.416
 ≤296353 (84.1%)1
 30-3915491 (59.1%)1.75 (0.90-3.22)
 40-4918079 (43.9%)1.41 (0.70-2.83)
 ≥509026 (28.9%)1.65 (0.67-3.91)
Occupation.278
 Farmer7120 (28.2%)1
 Staff12886 (67.2%)0.57 (0.25-1.27)
 Self-employed and service15489 (57.8%)0.63 (0.29-1.33)
 Other13454 (40.3%)0.94 (0.46-1.93)
Education.002
 Illiterate and primary8449 (58.3%)1
 Secondary school255137 (53.7%)0.67 (0.36-1.23)
 College and above13863 (45.7%)0.25 (0.11-0.57)
Monthly income.461
 <3000208116 (55.8%)1
 3000-500011660 (51.7%)1.02 (0.60-1.73)
 5100-80008539 (45.9%)1.26 (0.70-2.23)
 >80007834 (43.6%)1.58 (0.86-2.91)
Religious belief.585
 Yes2212 (54.5%)1
 No465237 (51.0%)1.35 (0.47-3.90)
Marital status.327
 Married458242 (52.8%)1
 Single297 (24.1%)0.63 (0.25-1.60)
Childbearing history.002
 07540 (53.3%)1
 1239153 (64.0%)0.33 (0.16-0.67)
 ≥217356 (32.4%)0.58 (0.25-1.33)
Age at first sexual experience.082
 ≤2015761 (38.9%)1
 21-2317684 (47.7%)0.76 (0.45-1.28)
 ≥24154104 (67.5%)0.51 (0.28-0.92)
Number of sexual partners.285
 1381172 (45.1%)1
 27759 (76.6%)0.75 (0.16-0.76)
 ≥32917 (58.6%)0.49 (0.20=-1.25)
Sexual frequency.454
 ≥1/week278147 (52.9%)1
 <1/week209102 (48.8%)1.18 (0.76-1.83)
Contraceptive methods.019
 Condom193129 (66.8%)1
 IUD12058 (48.3%)1.77 (1.01-3.08)
 Other5718 (31.6%)1.90 (0.91-3.99)
 None11744 (37.6%)2.43 (1.36-4.35)
Smoking.543
 Yes104 (40.0%)1
 No477245 (51.4%)0.60 (0.12-3.10)
Drinking.895
 Yes3618 (50.0%)1
 No451231 (51.2%)0.90 (0.37-2.17)

Abbreviations: CI, confidence interval; IUD, intrauterine device; OR, odds ratio.

Table 5.

Logistic Regression Analysis of the Levels of Knowledge About the HPV Vaccine.

CharacteristicTotalKnowledgeOR (95%CI) P Value
Residence.145
 East28141 (14.6%)1
 Other region988 (8.2%)1.87 (0.76-4.60)
 Other province10815 (13.9%)0.66 (0.31-1.41)
Ethnicity.351
 Han40643 (10.6%)1
 Other8121 (26.0%)0.69 (0.32-1.50)
 Age.662
 ≤296312 (19.0%)1
 30-3915415 (9.7%)0.93 (0.40-2.12)
 40-4918019 (10.6%)0.88 (0.34-2.23)
 ≥509018 (20.0%)2.13 (0.45-9.97)
Occupation.044
 Farmer717 (9.60%1
 Staff12820 (15.6%)3.98 (1.12-14.01)
 Self-employed and service15419 (12.3%)4.60 (1.37-15.50)
 Other13417 (12.7%)1.77 (0.58-5.40)
Education.001
 Illiterate and primary8412 (14.3%)1
 Secondary school25519 (7.5%)0.21 (0.05-0.80)
 College and above13833 (23.9%)0.06 (0.01-0.27)
Monthly income.170
 <300020823 (11.6%)1
 3000-50001166 (5.2%)2.23 (0.93-5.50)
 5100-80008517 (20.0%)1.02 (0.46-2.30)
 >80007818 (23.1%)0.73 (0.33-1.64)
Religious belief.507
 Yes222 (9.1%)1
 No46562 (133.3%)1.75 (0.34-9.09)
Marital status.358
 Married45857 (12.4%)1
 Single297 (24.1%)1.69 (0.55-5.16)
Childbearing history.929
 07516 (21.3%)1
 123935 (14.6%)0.94 (0.40-2.20)
 ≥217313 (7.5%)1.10 (0.36-3.42)
Sexual partners.027
 138140 (10.5%)1
 27720 (26.0%)0.35 (0.16-0.76)
 ≥3294 (13.8%)0.70 (0.19-2.58)
Sexual frequency.662
 ≥1/week27838 (13.7%)1
 <1/week20926 (12.4%)1.15 (0.61-2.15)
Contraceptive methods.716
 Condom19335 (18.1%)1
 IUD12015 (12.5%)0.97 (0.45-2.10)
 Other576 (10.5%)0.68 (0.22-2.08)
 None1178 (6.8%)1.43 (0.56-3.62)
Smoking.666
 Yes101 (10%)1
 No47763 (13.2%)0.59 (0.05-6.66)
Drinking.766
 Yes366 (16.7%)1
 No45158 (12.9%)1.20 (0.37-3.80)

Abbreviations: CI, confidence interval; IUD, intrauterine device; OR, odds ratio.

Logistic Regression Analysis of the Levels of Knowledge About Cervical Cancer. Abbreviations: CI confidence interval; IUD, intrauterine device; OR, odds ratio. Logistic Regression Analysis of the Levels of Knowledge about HPV. Abbreviations: CI, confidence interval; IUD, intrauterine device; OR, odds ratio. Logistic Regression Analysis of the Levels of Knowledge About the HPV Vaccine. Abbreviations: CI, confidence interval; IUD, intrauterine device; OR, odds ratio.

Discussion

Vaccination against HPV is a possible long-term solution for eradicating cervical cancer in developing countries, particularly in China, where a prophylactic HPV vaccine has already been approved. Yunnan province has a unique geographical location, highly complex topography, and large variations in elevation. Yunnan Province is a land of 26 Chinese ethnic groups. The health-care facilities in this region are inadequate, and there is a lack of well-organized cancer registries and gynaecological screening and HPV testing programs. In 2014, our group took initiative and reported HPV prevalence and its genotype distribution among various ethnic groups in Yunnan province.[14-16] Recently, cervical cancer screening test is available in almost all public hospitals. The current study is the first to assess the levels of awareness and knowledge about cervical cancer, HPV, and the HPV vaccine among women in the Yunnan province, which is a developing area located in the southwest of China. Considering the substantial differences in the levels of knowledge and awareness about HPV-related cancer, HPV, and HPV vaccine acceptance among women across the world, and especially in China, this survey will be helpful for designing strategies for cervical cancer control via HPV screening and vaccination in Yunnan province, China. The findings indicate a good level of knowledge and awareness about cervical cancer (85.4%); however, the level of knowledge and awareness about HPV was moderate (51.1%), and the level of knowledge and awareness about the HPV vaccine was very low (15.4%). Numerous previously reported surveys have demonstrated that 50% to 85% of women know about cervical cancer in Asia,[17,18] which is in accordance with the observations of our study. Human papillomavirus awareness was higher in Denmark (75.8%) and Sweden (74.8%) compared with Norway (62.4%) and Senegal (63%),[19,20] while studies from Yunnan, China (52.6%), Xinjiang, China (0.14%, 10 out of 7100), and Brazil (37%) have reported low levels of knowledge and awareness about HPV that are consistent with the findings of this study.[13,21,22] However, the levels of knowledge and awareness about HPV observed in the present study are higher than those in previously reported studies[13,23] but are still low. A low level of knowledge about HPV is recognized as a major hurdle for the implementation HPV vaccination programs. Therefore, it is very important that persistent public education efforts be initiated to communicate the information to the population through printed, electronic and social media, and debates with medical doctors and workers to raise awareness about HPV infection and the HPV vaccine. Yunnan province is located at the threshold of the Himalayas in the south of the People’s Republic of China and has a unique geographic location, a highly complex topography, and large variations in elevation. Different regions of Yunnan province have distinct topographical features. Northwestern Yunnan is a sparsely populated area with large mountains, a dry landscape, and cold weather. The southeast region is highly populated, the land is flat, and the weather is hot. We determined the levels of knowledge and awareness about HPV-related cancer, HPV, and the HPV vaccine among HPV-positive and -negative women. We found that knowledge about cervical cancer was higher among HPV-negative than HPV-positive women. However, knowledge about HPV and its vaccine was substantially higher among the HPV-positive than the HPV-negative women. It is well-established that the levels of knowledge and awareness about HPV and its vaccine are very heterogeneous among the general population and specific target groups.[24-26] Some studies have revealed very low levels of awareness,[27,28] eg, the level of knowledge and awareness about HPV and its vaccine among Danish women is 10%,[29] which is very low compared with the observations of the present study. This difference might be due to the massive HPV and HPV vaccination awareness campaign organized by the Ministry of Health and implemented through electronic and print media during cervical cancer screenings. In the present study, the level of knowledge about the HPV vaccine was very low (15.1%), and a similar level has been reported in Brazil.[22] We suggest the prioritization of the initiation of a high-level public education campaign regarding the HPV vaccine that will explicitly address knowledge deficits among general populations. Most of the participants stated that they would be vaccinated if the vaccine was available free of cost. Many studies have reported favorable attitudes toward vaccination in China[13,21,23] and other countries.[17,22] Yunnan is an underdeveloped province of China, and the poverty level is slightly higher than that of the rest of China; thus, many people in this province do not have enough money to pay for the HPV vaccine. Based on these observations, we suggest that the HPV vaccine must be introduced in Yunnan province under a government-subsidized program rather than by the private sector. Another main barrier to vaccination acceptance is concern about side effects. A lack of knowledge about HPV may make it difficult for women to make appropriate decisions. Therefore, clear and sustained educational programs may be needed in both rural and urban areas before the initiation of an HPV vaccination campaign. The limitations of this study include the fact that the sample was not representative of the general Yunnan population because recruitment was limited to one region of the province. Further extended quantitative and qualitative research involving other areas of the country will provide more relevant information on this issue.

Conclusion

In this study, we found high acceptability of the HPV vaccine in Chinese women and high awareness about cervical cancer. However, very low levels of knowledge about HPVs and their role in cancer development among the recruited women is alarming. Therefore, it is very important to initiate educational programs to raise awareness and knowledge about cervical cancer, HPV, and the HPV vaccine in this region.
  29 in total

1.  US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.

Authors:  Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman
Journal:  J Natl Cancer Inst       Date:  2015-04-29       Impact factor: 13.506

2.  Awareness of human papillomavirus after introduction of HPV vaccination: a large population-based survey of Scandinavian women.

Authors:  Louise T Thomsen; Mari Nygård; Signe Stensen; Bo Terning Hansen; Lisen Arnheim Dahlström; Kai-Li Liaw; Christian Munk; Susanne K Kjaer
Journal:  Eur J Cancer Prev       Date:  2017-03       Impact factor: 2.497

3.  Knowledge and awareness of human papillomavirus (HPV), cervical cancer and HPV vaccine among women in two distinct Nepali communities.

Authors:  Derek Christopher Johnson; Madhav Prasad Bhatta; Santosh Gurung; Shilu Aryal; Pema Lhaki; Sadeep Shrestha
Journal:  Asian Pac J Cancer Prev       Date:  2014

4.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Authors:  Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

5.  Human papillomavirus vaccine awareness, acceptability, and decision-making factors among Chinese college students.

Authors:  Shao-Ming Wang; Shao-Kai Zhang; Xiong-Fei Pan; Ze-Fang Ren; Chun-Xia Yang; Zeng-Zhen Wang; Xiao-Hong Gao; Man Li; Quan-Qing Zheng; Wei Ma; Fang-Hui Zhao; You-Lin Qiao; Priya Sivasubramaniam
Journal:  Asian Pac J Cancer Prev       Date:  2014

6.  Anal Cancer Incidence in the United States, 1977-2011: Distinct Patterns by Histology and Behavior.

Authors:  Meredith S Shiels; Aimée R Kreimer; Anna E Coghill; Teresa M Darragh; Susan S Devesa
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-07-29       Impact factor: 4.254

7.  Epidemiologic characterization of human papillomavirus (HPV) infection in various regions of Yunnan Province of China.

Authors:  Zulqarnain Baloch; Yuanyue Li; Tao Yuan; Yue Feng; Yanqing Liu; Wenlin Tai; Li Liu; Binghui Wang; A-Mei Zhang; Xiaomei Wu; Xueshan Xia
Journal:  BMC Infect Dis       Date:  2016-05-26       Impact factor: 3.090

8.  Knowledge of Greek adolescents on human papilloma virus (HPV) and vaccination: A national epidemiologic study.

Authors:  Dennis Vaidakis; Irini Moustaki; Ioannis Zervas; Anastasia Barbouni; Kyriaki Merakou; Maria S Chrysi; George Creatsa; Theodoros Panoskaltsis
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

9.  Knowledge of cervical cancer and Pap smear among Uyghur women from Xinjiang, China.

Authors:  Guzhalinuer Abulizi; Tangnuer Abulimiti; Hua Li; Guzhalinuer Abuduxikuer; Patiman Mijiti; Su-Qin Zhang; Ayinuer Maimaiti; Muyasier Tuergan; Ayiguli Simayi; Miherinisha Maimaiti
Journal:  BMC Womens Health       Date:  2018-01-17       Impact factor: 2.809

10.  Knowledge and Awareness of Cervical Cancer, Human Papillomavirus (HPV), and HPV Vaccine Among HPV-Infected Chinese Women.

Authors:  Zulqarnain Baloch; Nafeesa Yasmeen; Yuanyue Li; Wenhui Zhang; Hongyu Lu; Xiaomei Wu; Xueshan Xia; Shihua Yang
Journal:  Med Sci Monit       Date:  2017-09-04
View more
  7 in total

Review 1.  Current issues facing the introduction of human papillomavirus vaccine in China and future prospects.

Authors:  Li Ping Wong; Liyuan Han; Hui Li; Jinshun Zhao; Qinjian Zhao; Gregory D Zimet
Journal:  Hum Vaccin Immunother       Date:  2019-07-16       Impact factor: 3.452

2.  HPV vaccine acceptability and willingness-related factors among Chinese adolescents: a nation-wide study.

Authors:  Xi Zhang; Zengzhen Wang; Zefang Ren; Zhifang Li; Wei Ma; Xiaohong Gao; Rong Zhang; Youlin Qiao; Jing Li
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

3.  Awareness of human papillomavirus infection complications, cervical cancer, and vaccine among the Saudi population. A cross-sectional survey.

Authors:  Mazen M Almehmadi; Magdi M Salih; Ayman S Al-Hazmi
Journal:  Saudi Med J       Date:  2019-06       Impact factor: 1.484

4.  Characterization of the Genomic Landscape in Cervical Cancer by Next Generation Sequencing.

Authors:  Ling Qiu; Hao Feng; Hailin Yu; Ming Li; Yana You; Shurong Zhu; Wenting Yang; Hua Jiang; Xin Wu
Journal:  Genes (Basel)       Date:  2022-01-31       Impact factor: 4.096

5.  circRNA_0000285 knockdown suppresses viability and promotes apoptosis of cervical cancer cells by sponging microRNA-654-3p.

Authors:  Sisi Zhang; Yingping Xu; Qingyu Zheng
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

6.  Knowledge and awareness of human papillomavirus infection and human papillomavirus vaccine among Kazakhstani women attending gynecological clinics.

Authors:  Torgyn Issa; Aisha Babi; Alpamys Issanov; Ainur Akilzhanova; Kadisha Nurgaliyeva; Zauresh Abugalieva; Azliyati Azizan; Saleem A Khan; Chee Kai Chan; Raushan Alibekova; Gulzhanat Aimagambetova
Journal:  PLoS One       Date:  2021-12-13       Impact factor: 3.240

7.  Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control.

Authors:  Ting-Miao Wu; Ji-Bin Liu; Yu Liu; Yi Shi; Wen Li; Gao-Ren Wang; Yu-Shui Ma; Da Fu
Journal:  Cancer Control       Date:  2020 Jul-Aug       Impact factor: 3.302

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.